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Abstract
Resistance to cisplatin-based therapy is a major cause of treatment failure in human ovarian cancer. A better
understanding of the mechanisms of cisplatin resistance will offer new insights for novel therapeutic strategies for this
deadly disease. Akt and p53 are determinants of cisplatin sensitivity. Rictor is a component of mTOR protein kinase
complex 2, which is required for Akt phosphorylation (Ser473) and full activation. However, the precise role of rictor
and the relationship between rictor and p53 in cisplatin resistance remains poorly understood. Here, using sensitive
wild-type p53 (OV2008 and A2780s), resistant wild-type p53 (C13* and OVCAR433), and p53 compromised
(A2780cp, OCC1, and SKOV-3) ovarian cancer cells, we have demonstrated that (i) rictor is a determinant of
cisplatin resistance in chemosensitive human ovarian cancer cells; (ii) cisplatin down-regulates rictor content by
caspase-3 cleavage and proteasomal degradation; (iii) rictor down-regulation sensitizes chemo-resistant ovarian
cancer cells to cisplatin-induced apoptosis in a p53-dependent manner; (iv) rictor suppresses cisplatin-induced
apoptosis and confers resistance by activating and stabilizing Akt. These findings extend current knowledge on the
molecular and cellular basis of cisplatin resistance and provide a rationale basis for rictor as a potential therapeutic
target for chemoresistant ovarian cancer.
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Introduction
Epithelial ovarian cancer is the most lethal gynecologic
malignancy among women worldwide [1]. Despite advances in
our understanding of tumor biology, the overall mortality from
ovarian cancer (OVCA) remains high. Currently, chemotherapy
in combination with surgical debulking is the preferred
treatment option and derivatives of cisplatin (CDDP: cis-
diamminedichloroplatinum) are first-line chemotherapeutic
therapeutics. CDDP induces cytotoxic cell death through the
formation of DNA-platinum adducts, resulting in DNA damage
and activation of apoptotic pathways [2].
The effective treatment of OVCA is often hampered by late
diagnosis and the emergence of resistance to chemotherapy
after successive rounds of treatment. Resistance to
chemotherapeutics involves complex mechanisms that can
result from dysregulated signaling, enhanced DNA repair,
altered cancer cell metabolism [3,4], drug transport and
metabolism [5], and the dysregulation of survival factors,
including FLIP, Xiap and Akt [6-9]. These molecular and
cellular events alter the overall response of the cell to
genotoxic agents like CDDP and influence the cell toward pro-
survival decisions.
The mammalian target of rapamycin (mTOR) pathway has
emerged as a critical regulator of cellular metabolism, growth,
proliferation and survival. Its aberration, which is present in up
to 50% [10] of OVCA patients, has been shown to confer
resistance to CDDP-based treatment and is associated with an
adverse prognosis [11-14]. The mTOR pathway involves two
signaling complexes: mTORC1 and mTORC2. mTORC1 is
sensitive to rapamycin and controls protein synthesis and
cellular metabolism, while mTORC2 is essential for cell viability
[15]. mTORC2 is also known for its role in the phosphorylation
of Akt at Ser473 allowing full activation and proteasomal
degradation [16-18]. Akt activation and/or over-expression are
a determinant of CDDP sensitivity in human OVCA. Akt
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activation results in the stabilization of a number of caspase
inhibitors [19,20] inhibits mitochondrial p53 accumulation and
release of death proteins [21,22], and attenuates p53
phosphorylation and nuclear function [8]. In contrast, Akt
inhibition increases p53 phosphorylation (Ser15) and CDDP
sensitivity [8,23].
The rapamycin-insensitive companion of mTOR (Rictor) is an
essential component of the complex mTORC2, and is required
for its full function [24]. Over-expression of rictor increases
mTORC2 activity and promotes cell growth and motility [25].
Conversely, rictor down-regulation suppresses cell proliferation
and tumor formation in certain cancers [26-28]. Rictor also
interacts with the integrin-linked kinase (ILK) to promote cancer
cell survival through Akt Ser473 phosphorylation, and with
PKCζ for cancer cell invasion and metastasis [29,30]. Rictor is
required for prostate cancer development induced by PTEN
loss [31]. Targeting rictor induces cell cycle arrest at G1 phase
and decreases cyclin D1 expression in breast, colon and
prostate cancer cells [27,32]. Moreover, down-regulation of
mTORC2 facilitates chemotherapeutic drug-induced apoptosis
in breast cancer cells [33]. However, the role of rictor in CDDP
resistance in OVCA remains unknown.
p53 is a tumor suppressor protein that influences
downstream effectors of apoptosis through both transcription-
dependent and –independent mechanisms [8,21]. It is normally
activated by CDDP via phosphorylation at Ser15 and Ser20,
which are essential for its pro-apoptotic properties, and
suppression of murine double minute 2 (MDM2) and its
ubiquitination and proteasomal degradation [34-36]. We have
recently demonstrated that loss of p53 function by inactivation
or mutation negatively influences apoptosis and
chemosensitivity [7,37]. Cells lacking functional p53 fail to
inhibit mTORC1 in response to DNA damage [38]. However,
the coordination and communication between p53 status and
rictor in the regulation of chemoresistance is poorly
understood.
In the present study, we hypothesize that rictor plays an
important role in regulating chemosensitivity of OVCA cells and
that its down-regulation sensitizes chemoresistant OVCA cells
to CDDP treatment by facilitating Akt-dependent proteasomal
degradation, in a manner dependent upon p53 status. The
outcomes of this study raise the possibility that rictor may be a
therapeutic target for OVCA, although the effectiveness of such
an application is likely to be dependent on p53 status.
Materials and Methods
Reagents
RPMI 1640 and DMEM/F12 culture media, fetal bovine
serum (FBS), non-essential amino acids, penicillin,
streptomycin, and amphotericin B were from Life Technologies
(Carlsbad, CA, USA). CDDP, dimethyl sulfoxide (DMSO),
Hoechst 33248, aprotinin, sodium orthovanadate (Na 3VO4),
phenylmethylsulfonyl fluoride (PMSF) were from Sigma-Aldrich
(St. Louis, MO, USA). Rabbit polyclonal antibodies: anti-
phospho-Ser473-Akt, anti-phospho-Ser450-Akt, anti-Akt, anti-
phospho-Ser15-p53, anti-PARP and Rabbit monoclonal anti-
rictor antibody were purchased from Cell Signaling Technology
(Beverly, CA, USA). Mouse monoclonal anti-p53 and anti-
GAPDH antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and Abcam (Cambridge, MA, USA),
respectively. Goat anti-mouse and anti-rabbit secondary
antibodies were from Bio-Rad Laboratories (Hercules, CA,
USA). Rictor and p53 siRNA were purchased from Cell
Signaling Technology (Beverly, CA, USA). Control siRNA was
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Lipofectamine 2000, RNase A, N,N,N',N'-tetramethyl-
ethane-1,2-diamine (TEMED), TRIzol and ROX dye were from
Invitrogen (Carlsbad, CA, USA). RNeasy Mini Kit was from
Qiagen (Valencia, CA, USA). Adenovirus constructs containing
the wt-p53 and eGFP transcripts were from Vector Biolabs
(Philadelphia, PA, USA). Epoxomycin and lactacystin were
from EMD Chemical (Gibbstown, NJ, USA). Z-DEVD-FMK and
Z-VAD-FMK were from Tocris Bioscience (Ellisville, MO, USA).
Rictor and GAPDH RNA primer were from Bioneer (Daejeon,
Korea) and human recombinant active caspase 3 was from
BioVision (Mountain View, CA, USA). PIPES, DL-Dithiothreitol
(DDT), Ethylenediamine-tetraacetic Acid (EDTA) and 3[(3-
cholamido-propyl) dimethyallonio]-1-propanesulfonate hydrate
(Chaps) were purchased from Sigma-Aldrich (Saint Louis, MO,
USA).
Cell lines and Culture
CDDP sensitive (OV2008 and A2780s) and resistant (C13*,
OVCAR-433, A2780cp, OCC-1, and SKOV3) human OVCA
cell lines were generously provided by Drs. Rakesh Goel and
Barbara Vanderhyden (Ottawa Hospital Cancer Center,
Ottawa, ON, Canada). The cells were maintained in RPMI
1640 and DMEM/F-12 as previously reported [20,21,36]. The
OV2008 cell line and its resistant counterpart C13* were
originated from ovarian endometrioid adenocarcinoma with
squamous differentiation. OCC-1, A2780s and A2780cp cells
originated from undifferentiated ovarian carcinoma tumors.
SKOV3 cells were of a clear cell carcinoma origin [39] and
OVCAR433 cells were of serous cystadenocarcinomas of the
ovary [23]. Following the indicated treatments, the cells were
harvested for analysis.
Protein extraction and Western blotting analysis
The procedures for protein extraction and Western blotting
analysis were performed as previously described [40].
Membranes were incubated at 4°C overnight with anti-rictor
(1:100), phospho-Ser473-Akt (1:1000), phospho-Ser450-Akt
(1:1000), p53 (1:5000), phospho-Ser15-p53 (1:1000) and PARP
(1:2000) antibodies and 1 h at room temperature for anti-
GAPDH (1:10,000) and HRP-conjugated rabbit or mouse
secondary antibodies (1:5000-1:10,000). GAPDH was chosen
as loading control since its cellular content in the OVCA cells
examined in the current studies is not affected by CDDP
treatment. Band densities were analyzed for quantification
using a ChemiDOCTM XRS+ (Bio-Rad Laboratories, Hercules,
CA, USA)
Assessment of Apoptosis
Apoptosis was assessed based on cellular morphology using
the nuclear stain Hoechst 33258. The procedure was
Rictor Contributes to Chemoresistance in OVCA
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e75455
performed as previously described [20,36]. A minimum of 400
cells per treatment group were counted and the counter was
blinded to avoid experimental bias.
siRNA transfection
OVCA cells were transfected with rictor siRNA (0-100 nM; 48
h), p53 siRNA (100 nM; 48 h), or control siRNA (0-100 nM; 48
h) and treated thereafter with CDDP (0-10 µM; 24 h), as
previously described [20], and harvested for further analysis.
Adenoviral infection
A2780cp and SKOV3 cells were infected with adenoviral wt-
p53 (MOI = 10; 24 h; GFP as control) as previously described
[9,20].
In Vitro caspase-3 activity
The in vitro caspase-3 activity assay was performed with
whole cell lysates of OV2008 as previously described [23].
Statistical analysis
Results are expressed as the mean ± SEM of at least three
independent experiments. Statistical analysis was performed
by paired t-test, and one-way or two-way ANOVA as
appropriate, using SigmaPlot® 12 (Systat Software Suite, IL,
USA). Differences between multiple experimental groups were
determined by the Bonferroni post-hoc test. Statistical
significance was inferred at P < 0.05.
Results
CDDP down-regulates Rictor content and induces
apoptosis in chemosensitive but not resistant OVCA
cells
To determine whether rictor content is altered during CDDP
treatment in OVCA, chemosensitive OVCA (OV2008 and
A2780s) and chemoresistant (C13*, A2780cp*, OVCAR433,
OCC1 and SKOV-3) OVCA cell lines were treated with CDDP
(0-10 µM; 24 h) and rictor content was assessed by
immunoblotting [Figure 1]. CDDP significantly down-regulated
intact rictor content (200 kDa) and induced apoptosis in
chemosensitive (OV2008, ***P<0.001; and A2780s, **P<0.01),
but not in chemoresistant OVCA irrespective of CDDP
concentration (C13*, A2780cp, OVCAR433, OCC1 and
SKOV-3; p>0.05). These results demonstrate that rictor is not
subjected to down-regulation by CDDP in chemoresistant
OVCA cells, a phenomenon that may contribute to the resistant
phenotype.
CDDP induces rictor processing and chemosensitivity
in a caspase-3- and proteasome-dependent manner
To determine if CDDP-induced rictor down-regulation could
be due to post-translational processing, we first investigated
the possibility of caspase-dependent cleavage of rictor in
OV2008 and A2780s when treated with the pan-caspase
inhibitor Z-VAD FMK (10 µM) before (30 min) and during CDDP
challenge (0-10 µM; 24 h). OV2008 cells treated with CDDP
alone exhibited an intact rictor (200 kDa) and two
immunoreactive cleaved products which migrated at 160 kDa
and 130 kDa [Figure 2]. CDDP decreased intact rictor content
and the 160 kDa protein but markedly increased the levels of
130 kDa band. Although treatment of A2780s with CDDP also
resulted in down-regulation of intact rictor (200 kDa), the level
of the 160 kDa protein was markedly elevated while that of the
130 kDa was not significant affected. Pre-treatment of the cells
with the caspase inhibitor significantly attenuated the CDDP-
induced changes in intact and cleaved rictor contents in both
sensitive cells (P<0.05 and P<0.01 in OV2008 and A2780s,
respectively, Figure 2), suggesting that CDDP down-regulates
rictor in part by increased caspase activity and that cleavage at
different caspase consensus sites may be involved. In addition,
pretreatment of the OVCA cells with the specific caspase-3
inhibitor Z-DEVD-FMK produced similar results, indicating that
caspase-3 is involved in CDDP-induced rictor processing.
Interestingly, while CDDP induced apoptosis in both
chemosensitive cell lines, pretreatment of the cells with either
the pan-caspase or specific caspase-3 inhibitor attenuated this
response, suggesting that CDDP induces rictor processing by
caspase-3 and dysregulation of this process confers
chemoresistance in OVCA cells.
To determine whether proteasomal degradation plays a role
in CDDP-induced rictor down-regulation, OV2008 cells were
cultured [30 min pre-treatment; 24 h during treatment with
CDDP (0-10 µM)] with the proteasome inhibitors epoxomycin
(10 nM) and lactacystin (4 µM). Whereas CDDP alone
significantly down-regulated intact rictor and induced apoptosis,
as expected, the presence of the inhibitors completely blocked
CDDP-induced rictor down-regulation and significantly, but not
completely attenuated apoptosis, as evidenced by PARP
cleavage and nuclear morphology (P<0.001; Figure 3: A).
We then investigated further if rictor processing by
caspase-3 activity and proteasomal degradation occurs in
separate pathways. OV2008 cells were cultured [30 min pre-
treatment; 24 h during treatment with CDDP (0-10 µM)] with
proteasome inhibitors and/or specific caspase-3 inhibitor. The
same results were observed when either inhibitor was present.
However, no additional effect was observed when both
inhibitors were used together [Figure 3: B].
In addition, to provide further evidence that rictor processing
induced by CDDP treatment is caspase-3 dependent, whole
cell lysates from OV2008 cells were used to perform an in vitro
caspase-3 activity assay. The in vitro data was in agreement to
that obtained from the cell line experiment [Figure 3: C]. Taken
together, these results indicate that CDDP down-regulates
intact rictor at the protein level via caspase-3 cleavage and
proteasomal degradation.
Rictor knockdown sensitizes chemo-resistant OVCA to
CDDP-induced apoptosis
To establish the role of rictor in OVCA chemoresistance,
rictor expression in a wt-p53 chemoresistant OVCA cell line
(C13*) was silenced by siRNA (0, 50 and 100 nM; 48 h) prior to
treatment with CDDP (10 µM; 24 h), and apoptosis was
assessed. Intact rictor and its cleaved forms were significantly
down-regulated by siRNA in a concentration-dependent
manner. A significant decrease in intact rictor and cleaved
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rictor were observed at 50 nM (p<0.05) and to an approximate
30% reduction at 100 nM, irrespective of the presence of
CDDP. These findings not only confirmed that the 160kDa and
130 kDa immunoreactive bands were indeed cleaved products
of rictor, but also demonstrated that rictor knockdown induced
apoptosis (p<0.05) as well as enhanced CDDP-induced
apoptosis in a concentration-dependent manner (p<0.001)
[Figure 4]. These results suggest that rictor is an important
determinant of CDDP resistance in OVCA.
Apoptotic response to CDDP following rictor down-
regulation is dependent on p53 status
The tumor suppressor p53 is an important mediator of
CDDP-induced apoptosis [9,22]. Since approximately 50% of
OVCA patients carry TP53 gene mutation(s) [41], it is of
interest to determine if CDDP-induced apoptosis in
chemoresistant cells following rictor knockdown is dependent
on the presence of a functional p53. To investigate this
possibility, rictor expression in chemoresistant OVCA cell lines
with varying p53 status (wt-p53, C13* and OVCAR433; p53-
mutant, OCC1 and A2780cp; p53-null, SKOV3) were silenced
with rictor siRNA (100 nM siRNA, 48 h) prior to treatment with
CDDP (0-10 µM, 24 h). Rictor knock-down significantly
sensitized chemoresistant wt-p53 cells (C13* and OVCAR433,
Figure 5: A; P<0.001) but not p53-deficient cells (OCC1, Figure
6: A; A2780cp and SKOV3, Figure 5: B) to CDDP-induced
apoptosis, suggesting that a functional p53 might be needed
for CDDP-induced apoptosis in the chemoresistant OVCA cells
with rictor knockdown. To further investigate this hypothesis,
CDDP-resistant OVCA cell lines harboring a p53 mutation
Figure 1.  CDDP down-regulates rictor content and induces apoptosis in chemosensitive but not resistant OVCA cells in
vitro.  Rictor protein expression is down-regulated in chemosensitive (OV2008 and A2780s) but not chemoresistant OVCA (C13*
and A2780cp*) during CDDP treatment (0-10 µM CDDP; 24 h). Decreased rictor content in OV2008 and A2780s following CDDP
treatment was associated with increased apoptosis. Rictor protein content in chemoresistant OVCA (OVCAR433, OCC1 and
SKOV3) was not affected by CDDP. Rictor content was normalized against GAPDH (loading control). A representative Western blot
from three independent experiments is shown. Results are presented as mean ± SEM of three independent experiments. *p<0.05,
**p<0.01, ***p<0.001, #p<0.05 (vs CTL in sensitive cells). Hoechst 33258 staining was used for assessment of apoptosis as
mentioned in experimental procedures.
doi: 10.1371/journal.pone.0075455.g001
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Figure 2.  CDDP-induced rictor downregulation in CDDP-sensitive cells involves caspase-3-mediated cleavage.  OV2008
and A2780s were pretreated with Z-VAD FMK (10 µM) and Z-DEVD FMK (50 µM) for 30 minutes before and during CDDP
challenge (0-10 µM; 24 h) and rictor content and apoptosis were assessed. OV2008 cells treated with CDDP alone exhibited an
intact rictor (200 kDa) and two cleaved products (160 kDa and 130 kDa). CDDP decreased intact rictor content and 160 kDa protein
but markedly increased levels of the 130 kDa band. Treatment of A2780s with CDDP resulted in down-regulation of intact rictor but
increased the level of the 160 kDa protein and had no effect on the 130 kDa protein. Pre-treatment of the cells with the pan-caspase
inhibitor (Z-VAD) or the specific caspase-3 inhibitor (Z-DEVD) significantly attenuated the CDDP-induced changes in intact and
cleaved rictor contents in both sensitive cells, and CDDP-induced apoptosis was significantly but not completely attenuated by the
presence of the inhibitors in both chemosensitive cell lines. Rictor content was normalized against GAPDH (loading control). Results
are presented as mean ± SEM (n=3 and n=5 in OV2008 and in A2780s, respectively). *p<0.05, **p<0.01, ***p<0.001 (vs respective
controls). Hoechst 33258 staining was used for assessment of apoptosis as mentioned in experimental procedures.
doi: 10.1371/journal.pone.0075455.g002
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Figure 3.  Proteasome-mediated degradation and caspase-3 activity are responsible for CDDP-induced rictor down-
regulation in chemosensitive OVCA.  A. OV2008 cells were pretreated (30 min) with the proteasomal inhibitors [epoxomycin (10
nM) and lacytasystin (4 µM)] and subjected to CDDP challenge (0-10 µM; 24 h). Rictor content and apoptosis were analyzed by
Western blotting and nuclear morphology assessment. Both epoxomicin and lactacystin effectively blocked CDDP-induced rictor
degradation (P<0.001) but only partially attenuated apoptosis. B. OV2008 cells were cultured in the same conditions as in A, but
pretreated with proteasome inhibitor and/or Z-DEVD (50 µM). No synergistic effect between the two inhibitors was observed. C.
Incubation of OV2008 whole cell lysate (30 min, 30°C) with recombinant active caspase-3 (5-20 µg/ml) resulted in Rictor cleavage
as evidenced by decreased intact rictor content (200 kDa) and increased in the cleaved forms (130 kDa and 160 kDa). Results are
presented as mean ± SEM of three independent experiments. *p<0.05, **p<0.01, ***p<0.001 (vs respective controls). Hoechst
33258 staining was used for assessment of apoptosis as mentioned in experimental procedures.
doi: 10.1371/journal.pone.0075455.g003
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(A2780cp) and a p53-null line (SKOV-3) were treated with rictor
siRNA (0-100 nM; 48 h), followed by reconstitution of wt-p53
via adenoviral infection (0-10 MOI; 24 h) and CDDP treatment
(0-10 µM CDDP; 24 h). As shown in Figure 5: B, while rictor
knockdown alone did not significantly increase CDDP
sensitivity in the absence of wt-p53, wt-p53 reconstitution
significantly enhanced the effects of rictor-knockdown on
CDDP-induced phospho-p53 Ser15 content and apoptosis in
both p53-deficient cell lines (P<0.001).
Rictor down-regulation sensitizes chemoresistant cells
to CDDP-induced apoptosis by facilitating Akt
proteasomal degradation
Rictor is known to be required for mTORC2 to phosphorylate
Akt at Ser473. To examine if and how Akt is relevant to this
phenomenon, chemoresistant OVCA cells (C13*) rictor
expression was silenced by siRNA (100 nM; 48 h) prior to pre-
treatment with epoxomycin (12.5 nM; 30 min) and treatment
with CDDP (10 µM; 24 h), and apoptosis was assessed. Rictor
knockdown alone increased phospho-Akt (Ser473) content but
decreased the levels of phospho-Akt Ser450 [Figure 6], a
phosphorylation site known to be regulated in Akt stability [18].
The increase in Akt phosphorylation at Ser473 following rictor
silencing without the proteasomal inhibitor was accompanied
by Akt down-regulation (P<0.05 in treatment group) and was
rescued by proteasomal inhibitor (p<0.05). Apoptosis induction
irrespective of the presence of CDDP, two responses
attenuated by the presence of the proteasome inhibitor
epoxomycin (Figure 6; P<0.05 and P<0.001 in control and
CDDP treatment groups respectively). Moreover, the ratio
between phospho-Akt at Ser473 and total Akt was also
markedly increased in rictor knockdown with CDDP-treatment
and significantly decreased when epoxomicin was added
(P<0.001 and p<0.05; with and without epoxomycin,
Figure 4.  Rictor knockdown sensitizes chemoresistant OVCA cells to CDDP-induced apoptosis.  C13* cells were transfected
with rictor siRNA (0-100 nM; 48 h) and cultured with or without CDDP (10 µM; 24 h). Rictor knockdown significantly enhanced
CDDP-induced apoptosis in C13* cells in a concentration-dependent manner. Results are expressed as mean ± SEM of three
independent experiments. *p<0.05, ***p<0.001 (vs respective CTL siRNA). Hoechst 33258 staining was used for assessment of
apoptosis as mentioned in experimental procedures.
doi: 10.1371/journal.pone.0075455.g004
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Figure 5.  Apoptotic response of chemoresistant OVCA cells to CDDP following rictor down-regulation is dependent on
p53 status.  Chemoresistant OVCA cell lines with varying p53 status (wt-p53, C13* and OVCAR433; p53-mutant, OCC1 and
A2780cp; p53-null, SKOV3) were transfected with rictor siRNA (100 nM siRNA, 48 h) with or without adenoviral wt-p53 infection
(0-10 MOI; 24 h; p53-deficient cells) and CDDP treatment (0-10 µM CDDP; 24 h). Rictor, p-p53 ser15, p53, PARP and GAPDH
content, as well as apoptosis were assessed. Rictor knock-down significantly sensitized chemoresistant wt-p53 cells (A, C13* and
OVCAR433; P<0.001) but not p53-difficient cells (A, OCC1; B, A2780cp and SKOV3) to CDDP (10 µM)-induced apoptosis.
Reconstitution in A2780cp and SKOV-3 of wt-p53 significantly enhanced CDDP-induced apoptosis (P<0.001). Results are
presented as mean ± SEM of three independent experiments. *p<0.05, **p<0.01, ***p<0.001 (vs respective CTL siRNA), # #
#p<0.05 (vs controls Adenoviral infection). Hoechst 33258 staining was used for assessment of apoptosis as mentioned in
experimental procedures.
doi: 10.1371/journal.pone.0075455.g005
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Figure 6.  Rictor down-regulation sensitizes chemoresistant OVCA cells to CDDP-induced apoptosis by facilitating Akt
proteasomal degradation.  Chemoresistant OVCA cells (C13*) were transfected with rictor siRNA (100 nM siRNA, 48 h) and
pretreated with epoxomycin (0-12.5 nM) 30 minutes prior to CDDP treatment (0-10 µM CDDP; 24 h). Rictor, Akt, phospho- Akt
(Thr450 and Ser473), and GAPDH content, as well as apoptosis were assessed. Rictor knock-down significantly enhanced CDDP-
induced apoptosis in chemoresistant OVCA cells (P<0.01 and P<0.001, respectively) and this effect was rescued by epoxomycin
(P<0.05 and p<0.001, respectively) Total-Akt was significantly decreased during rictor silencing with CDDP treatment (P<0.05) and
a massive increase in the ratio between phospho-Akt (Ser473) and total-Akt was also observed, which significantly decreased when
epoxomycin was added (P<0.001 and P<0.05, respectively) Results are presented as mean ± SEM of three independent
experiments. *p<0.05, **p<0.01, ***p<0.001 (vs respective CTL siRNA), # #p<0.01, # # #p<0.05 (vs without epoxomycin). Hoechst
33258 staining was used for assessment of apoptosis as mentioned in experimental procedures.
doi: 10.1371/journal.pone.0075455.g006
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respectively). These results suggest that rictor plays a role in
Akt stabilization and CDDP resistance in human OVCA and its
knockdown promotes Akt proteasomal degradation and
enhances CDDP sensitivity.
Discussion
Chemoresistance is a major therapeutic hurdle in ovarian
cancer and its cellular mechanism is complex and poorly
understood. Although the mTOR signaling pathway is known to
promote cell proliferation and survival, whether rictor is
involved in the control of chemosensitivity is unknown. In the
present study, we have investigated the role of rictor in CDDP
resistance using CDDP-sensitive and resistant OVCA cell lines
with different p53 status. We have demonstrated for the first
time that rictor is a determinant of CDDP resistance in OVCA.
CDDP down-regulates rictor content in chemosensitive cells by
caspase-3 and proteasome-dependent degradation, but no
similar effect was observed in resistant cells. In addition, we
have shown that rictor suppresses CDDP-induced apoptosis
and confers resistance by activating and stabilizing Akt.
Silencing rictor sensitizes chemoresistant OVCA cells to
CDDP-induced apoptosis in cells harboring wild type-p53, but
not in p53-compromised cells unless reconstituted with a
functional p53. Taken together, these data support the
hypothesis that rictor down-regulation sensitizes
chemoresistant OVCA cells to CDDP treatment by facilitating
Akt-dependent proteasomal degradation, in a manner
dependent upon p53 status.
Our present investigation shows that rictor is down-regulated
at protein but not mRNA level (data not shown) and this
process is associated with CDDP-induced apoptosis in
sensitive OVCA cells and that rictor plays a role in cell fate
determination. This observation is further supported with
results using various chemoresistant OVCA cell lines with
different p53 status, in that the failure of CDDP to down-
regulate rictor content allows the cells to survive CDDP
treatment. The role of rictor in cell survival has previously been
demonstrated, and one study has addressed the notion that
rictor and proteins in the mTOR pathway are down-regulated
via the proteasome-ubiquitin pathway in lung cancer cells after
chemotherapeutic challenge, the possible involvement of rictor
processing in the control of chemosensitivity was not
addressed [26]. Our results showing that CDDP induces rictor
down-regulation via the proteasome are in agreement with this
finding. Moreover, our present studies have extended the
above findings by showing that caspase-3 is required for CDDP
–induced rictor processing in chemosensitive human OVCA
cells. Taken together, these results suggest that rictor confers
CDDP resistance in human OVCA and CDDP-induced rictor
down-regulation is dependent upon both caspase-3 activity and
proteasomal degradation in chemosensitive, but not in
chemoresistant OVCA cell lines.
Tumor suppressor TP53 is also one of the most frequently
mutated genes in human OVCA, and could be as high as 50%
in OVCA patients [41]. Loss or mutation of p53 can have an
enormous impact on tumor aggressiveness, prognosis and
successful implemention of treatment [42]. Since the
mechanism of CDDP-resistance is multifactorial and p53 status
is one of the major concerns in human OVCA, we have
investigated the relationship between rictor and the tumor
suppressor p53, in the aspect of chemoresistance. Our
investigation, therefore, further addresses the role of rictor in
CDDP resistance and shows that rictor knockdown not only
promotes apoptosis, but also enhances CDDP-induced
apoptosis in human OVCA cells. This result correlates with a
recent study showing that targeting of rictor prevents cell
migration and promotes apoptosis in breast cancer [23].
Results from our current study also show that sensitizing
chemoresistant OVCA cells by silencing rictor appears to
depend upon p53 status. This notion is further supported by the
observation that a combination of rictor knockdown and
reconstitution of wt-p53 enhances apoptosis in p53-
compromised cells when induced by CDDP treatment, an
outcome that does not eventuate without wt-p53. The latter
response is concomitant with an increase in p53 activation
through phosphorylation at the ser15 residue, which changes
p53 structure and inhibits the p53-MDM2 interaction, thereby
stabilizing p53 [35]. This could be the reason for p53
stabilization observed in A2780cp and SKOV-3 in the presence
of phospho-p53 (ser15). Taken together, these observations
suggest that rictor knockdown induces apoptosis and enhances
CDDP-induced apoptosis in a p53-dependent manner.
The Akt signaling pathway is a determinant of
chemoresistance and its activation promotes a chemoresistant
phenotype, frequently detected in as high as 87% of cases in
human OVCA [10]. The interplay between Akt and mTOR
complexes is essential for their cellular function and rictor is
known to be required for phosphorylation of Akt at both the
hydrophobic motif (Ser473) and the turn motif (Thr450),
allowing full activation and triggering Akt to proteasomal
degradation, respectively [17,18,43]. In the present study, we
have illustrated that rictor contributes to CDDP resistance in
human OVCA, in part by activating and stabilizing Akt.
Silencing rictor sensitizes human OVCA cells to CDDP-induced
apoptosis through facilitating Akt proteasomal degradation.
Although our findings are in contrast to previous studies
showing that rictor knockdown attenuates Akt phosphorylation
at Ser473 and function [27,31,33], mTORC2 disruption has
been reported to destabilize Akt due to its ability to
phosphorylate Akt at Ser 473 but not at Thr450, thus leading to
preferential degradation and inactivation [18,44]. These notions
are also supported by the further observation that Akt and
phospho-Akt (Thr450) content were decreased, consistent with
an increase in phospho-Akt (Ser473), when rictor expression
was silenced. This phenomenon could be rescued by a
proteasomal inhibitor. Although significantly increased levels of
phospho-Akt (Ser473) were not observed after rictor silencing
with CDDP treatment, that total-Akt content was decreased
significantly could be a reason. This observation was further
buttressed by the massive increase in the ratio between
phospho-Akt (Ser473) and total-Akt when treated with CDDP
with rictor knockdown. Conversely, phospho-Akt (Thr450) was
much higher in content in the cells without rictor knockdown,
resulting in Akt stabilization and promoting CDDP resistance.
Another observation is that phospho-Akt (Thr450) content was
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intimately related to total-Akt content. This could indicate that
phosphorylation of Akt at Ser473 is a predominant mechanism
steering Akt stability and degradation in human OVCA. Rictor
induced and enhanced CDDP-induced apoptosis which was
also attenuated by Akt stabilization following epoxomycin
treatment. Taken together, our findings suggest that rictor is
indispensable for mTORC2 to stabilize and activate Akt and
expands the current knowledge that rictor knockdown not only
attenuates Akt function, but also facilitates proteasomal
degradation.
In summary, we have demonstrated for the first time that
CDDP-induced rictor down-regulation involves caspase-3
cleavage and proteasomal degradation, and that rictor plays a
role in chemoresistance by promoting Akt activation and
stabilization in OVCA. This occurs in a p53-dependent manner.
To facilitate our future investigation on the precise role of rictor
in CDDP resistance in OVCA cells, we have proposed a
hypothetical model [Figure 7]. In chemosensitive cells, CDDP
activates caspase-3 and induces proteasomal degradation for
rictor processing, and consequently destabilizes mTORC2, the
unstable mTORC2 complex then facilitates Akt phosphorylation
at Ser473, an event known to promote Akt proteasomal
degradation and the induction of apoptosis. However, in
chemoresistant cells, high level of stabilized rictor promotes Akt
activation and stabilization, thereby contributing to CDDP
resistance. However, precisely how mTORC2 regulates Akt
phosphorylation and its site-specificity in the control of
chemosensitivity in ovarian cancer cells and whether DNA-
dependent protein kinase is also involved, remains to be
determined. The mechanism(s) by which caspase-mediated
processing and proteasomal degradation of rictor is regulated
and the interdependence of these processes also require
further investigation. Although Akt has been shown to be
ubiquitinated and degraded by the proteasome upon
phosphorylation at Ser 473 in both normal and malignant cells
[18], the molecular mechanism involved in Akt processing in
OVCA needs to be further demonstrated. Moreover, changes in
the half-life of Akt and its downstream events in response to
CDDP treatment and proteasomal inhibition needs to be
assessed so as to provide greater insights into the
consequences of Akt degradation and its influence on
chemosensitivity in OVCA cells. Establishing the role of rictor in
chemoresistance may justify the targeting of rictor as a novel
therapeutic strategy in overcoming CDDP resistance in human
OVCA, particularly for those with wt-p53 status. Targeting rictor
may potentiate effective therapeutic outcomes, since this is
likely to not perturb the negative feedback pathway between
Akt and mTORC1. However, our findings need to be verified in
vivo to support the validity of this hypothesis.
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Figure 7.  A hypothetical model illustrating the role of rictor in regulation of CDDP sensitivity in OVCA cells.  In
chemosensitive cells, CDDP activates caspase-3 and induces proteasomal degradation for rictor processing, and consequently
destabilizes mTORC2, The unstable mTORC2 complex then facilitates Akt phosphorylation at Ser473, an event known to promote
Akt proteasomal degradation and the induction of apoptosis. However, in chemoresistant cells, high level of stabilized rictor
promotes Akt activation and stabilization, thereby contributing to CDDP resistance.
doi: 10.1371/journal.pone.0075455.g007
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